Rimegepant: Effective Migraine Relief for Triptan-Intolerant Adults

Research Summary

In a new study published in Cephalalgia, researchers examined the efficacy and tolerability of rimegepant, a calcitonin gene-related peptide antagonist, for acute migraine treatment in adults unsuitable for triptans. This phase 4, randomized, double-blind, placebo-controlled trial involved 585 participants who had previously experienced intolerance, inefficacy, or contraindications to triptans. Participants received either a 75-mg dose of rimegepant orally disintegrating tablet or placebo. Rimegepant significantly outperformed placebo, with 55.9% achieving migraine pain relief at two hours compared to 32.7% in the placebo group. Secondary endpoints also favored rimegepant, and adverse event rates were comparable between groups. This trial highlights rimegepant as an effective alternative for those unable to use triptans.

Study Details

📄 Title: Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.

👥 Research Team: Ashina M et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.